Atlas Trials

An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.

Clinical trial NCT02397395 · WITHDRAWN

Trial details

NCT number
NCT02397395
Sponsor
Janssen R&D Ireland
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Renal ImpairmentEnd-stage Renal Disease
Start date
2015-05-01
Primary completion
2016-02-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.